AI Summary
This article discusses how early data suggests that a new monoclonal antibody class targeting pituitary adenylate cyclase-activating polypeptide signaling could be an effective approach for preventing migraines.
Early data support the concept that targeting pituitary adenylate cyclase–activating polypeptide signaling could be an effective new approach for migraine prevention.
Medscape Medical News